Simeprevir in combination with peginterferon and ribavirin theraphy for Japanese chronic HCV patients: Significance of hepatic transporter

Simeprevir in combination with peginterferon and ribavirin theraphy for Japanese chronic HCV patients: Significance of hepatic transporter - Hepatic transporter at simeprevir therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000014003

Enrollment

Registered

2014-05-21

Start date

2014-05-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis C

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Peginterferon alfa-2a or 2b and ribavirin theraphy for genotype 1 and high viral titer chronic hepatitis C 2)Judged by investigator not to be appropriate for inclusion in this study

Exclusion criteria

Exclusion criteria: estimated glomerular filtration rate <40

Design outcomes

Primary

Measure	Time frame
The relationship between hyperbilirubinemia and gene polymorphisms in hepatic transporter	—

Secondary

Measure	Time frame
The relationship between blood concentration of sipemrevir and hepatic enhancement with gadoxetic acid	—

Countries

Japan

Contacts

Public ContactHironao Okubo

Juntendo University Nerima Hospital Department of Gastroenterology

drokubo@juntendo-nerima.jp03-5923-3111

Outcome results